344 related articles for article (PubMed ID: 37234004)
21. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.
Baji P; Péntek M; Czirják L; Szekanecz Z; Nagy G; Gulácsi L; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S53-64. PubMed ID: 24832836
[TBL] [Abstract][Full Text] [Related]
22. Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Verhoef LM; van den Bemt BJ; van der Maas A; Vriezekolk JE; Hulscher ME; van den Hoogen FH; Jacobs WC; van Herwaarden N; den Broeder AA
Cochrane Database Syst Rev; 2019 May; 5(5):CD010455. PubMed ID: 31125448
[TBL] [Abstract][Full Text] [Related]
23. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
[No Abstract] [Full Text] [Related]
24. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
Kristensen LE; Christensen R; Bliddal H; Geborek P; Danneskiold-Samsøe B; Saxne T
Scand J Rheumatol; 2007; 36(6):411-7. PubMed ID: 18092260
[TBL] [Abstract][Full Text] [Related]
25. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
26. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
[TBL] [Abstract][Full Text] [Related]
27. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
28. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis.
Luo X; Du X; Li Z; Liu J; Lv X; Li H; Guo Q; Wang C; Xue X; Le K; Jiang X; Huang L; Yang Y
JAMA Netw Open; 2023 Oct; 6(10):e2337348. PubMed ID: 37824143
[TBL] [Abstract][Full Text] [Related]
29. A review of biosimilars for rheumatoid arthritis.
Conran CA; Moreland LW
Curr Opin Pharmacol; 2022 Jun; 64():102234. PubMed ID: 35552095
[TBL] [Abstract][Full Text] [Related]
30. Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis.
Hanrahan C; Lee T
Am J Health Syst Pharm; 2021 Mar; 78(8):697-704. PubMed ID: 33599738
[TBL] [Abstract][Full Text] [Related]
31. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
[TBL] [Abstract][Full Text] [Related]
34. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
Kay J; Jaworski J; Wojciechowski R; Wiland P; Dudek A; Krogulec M; Jeka S; Zielinska A; Trefler J; Bartnicka-Maslowska K; Krajewska-Wlodarczyk M; Klimiuk PA; Lee SJ; Bae YJ; Yang GE; Yoo JK; Furst DE; Keystone E
Arthritis Res Ther; 2021 Feb; 23(1):51. PubMed ID: 33546755
[TBL] [Abstract][Full Text] [Related]
36. The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis.
Lopez L; Griffier R; Barnetche T; Lhomme E; Kostine M; Truchetet ME; Schaeverbeke T; Richez C
Rheumatology (Oxford); 2022 Feb; 61(2):531-541. PubMed ID: 34382085
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
Jansen JP; Buckley F; Dejonckheere F; Ogale S
Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
[TBL] [Abstract][Full Text] [Related]
38. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A
J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
